Connect with us

Headlines

EternaTear Raises $4.9M in Funding

It’s developing a product for dry eye syndrome.

mm

Published

on

EternaTear, a startup company based in Raleigh, NC, has raised $4.9 million in funding, according to the North Carolina Biotechnology Center.

The company is working on a non-prescription product called EternaTear. It is an eyedrop intended to treat dry eye syndrome.

The Series A investment round was led by Carolina Angel Network and Keiretsu Forum, the North Carolina Biotechnology Center reports. Other investors included Band of Angels, Deep Work Capital, Duke Angel Network, Keiretsu Capital and various ophthalmologists, optometrists and others.

Tim Willis, CEO of EternaTear, was quoted saying that the funding “provides us the capital to develop our product for both the U.S. and European markets to help the 320 million globally who suffer from dry eye.”

The company’s immediate priorities include “completion of a multi-site clinical marketing study and U.S. Food and Drug Administration OTC registration,” according to the North Carolina Biotechnology Center.

Advertisement

Since launching in 2014, INVISION has won 23 international journalism awards for its publication and website. Contact INVISION's editors at editor@invisionmag.com.

SPONSORED VIDEO

Turn Patients Into Loyal Eyewear Shoppers

80% of patients are browsing eyewear online, are you influencing patients online before your competition? Join thousands of practices thriving with Optify, voted the #1 optical sales tool by EyeVote. Empower your opticians to save time, increase optical revenue, and maximize your EHR data and website with a seamless optical plug-in that keeps patients buying from YOU! Now through August 31st receive a $25 UberEats® gift card when you complete a 15 min demo. Book your demo here..

Promoted Headlines

Advertisement

Advertisement

Subscribe

INVISIONMAG.COM
BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Advertisement

Most Popular